Today's Trend
Surrozen, Inc. (NASDAQ: SRZN) is trading lower as investors digest a wave of mixed analyst updates following the company’s latest earnings report. While the stock had already reacted to a very large quarterly loss, the newest notes are adding to the uncertainty by showing both upward and downward revisions to future profit expectations.
- Lifesci Capital raised its estimates for Surrozen’s Q2, Q3, and Q4 2026 earnings, signaling slightly better near-term expectations than before. Source report
- HC Wainwright maintained a Buy rating and a $44 price target on SRZN, suggesting some analysts still see meaningful upside from current levels. Source report
- A head-to-head comparison article with Rigel Pharmaceuticals was published, but it does not appear to include a direct catalyst for Surrozen’s stock movement. Rigel Pharmaceuticals versus Surrozen Head to Head Comparison
- HC Wainwright cut its FY2026, FY2027, FY2028, FY2029, and FY2030 EPS estimates, pointing to continued expectations for significant losses over the next several years. Source report
- The company’s recent earnings release showed a far larger-than-expected quarterly loss, which likely remains a drag on investor sentiment. Source report
Overall, Surrozen (SRZN) appears to be under pressure because the market is focusing more on the company’s steep losses and lowered longer-term earnings outlook than on the modestly improved near-term estimates.